Challenges of building a new organisation in this field

Presented to ISCT Conference London
6th May 2017
Introduction to the Cell & Gene Therapy Catapult
Strategy

• Build a £10bn industry by 2035

• Licensed manufacturing and its supply chain creating 18,000 sticky jobs by 2035

• Increase clinical trial pipeline

• Businesses created leading to Advanced Therapy companies that succeed and stay in the UK

• Demonstrating that the UK is the place to do this work, with increased inward investment

The Cell and Gene Therapy Catapult mission:

“Growing the UK cell and gene therapy industry, delivering health and wealth.”
### The Cell & Gene Therapy Catapult today

<table>
<thead>
<tr>
<th>£125M</th>
<th>£28M</th>
<th>£13M</th>
<th>£55M</th>
</tr>
</thead>
<tbody>
<tr>
<td>£125 million <strong>investment</strong> into the Catapult programme</td>
<td><strong>Invested</strong> £28 million in projects over the last 4 years</td>
<td>Invested more than £13 million in a 1,200m² state-of-the-art development facility</td>
<td>Investing £55 million in 7,200m² large-scale GMP manufacturing centre in Stevenage</td>
</tr>
<tr>
<td>£51M</td>
<td>8</td>
<td>70+</td>
<td>130+</td>
</tr>
<tr>
<td>Leveraged £51 million of R&amp;D funding</td>
<td><strong>Eight</strong></td>
<td><strong>Collaborated on 70+ projects with 36 currently live</strong></td>
<td><strong>Over 130</strong> cell and gene therapy experts from health economists and regulatory experts to leading edge translational scientists</td>
</tr>
</tbody>
</table>

- **Eight**
  - Helped in the formation of eight spin out companies including three where we have led development of the technology

- **70+**
  - Collaborated on 70+ projects with 36 currently live

- **130+**
  - Over 130 cell and gene therapy experts from health economists and regulatory experts to leading edge translational scientists
A global outlook

A team of 130+ experts drawn from 24 countries based in London and Stevenage

1000+ UK jobs created
400 – 600 additional skilled staff required over next two years
40+ alumni in UK industry and academia
Responding to the needs of industry

KEY BARRIERS
1. Cost of goods and productivity
2. Manufacturing capacity
3. Skills shortage
4. Viral vector supply
5. Regulatory pathways (Brexit)
6. Clinical adoption
7. Reimbursement and risk

Catapult Solutions
Solution: Large-scale GMP manufacturing centre in Stevenage

- Unique **collaborative business model** to enable companies to scale up manufacture

- **Adaptable** to multiple processes whether allogeneic, autologous or viral vector

- Excellent **logistics** infrastructure

- **Cluster** development

- Access to **great people and talent**
Access to Great People & Talent

• **Industry skills demand survey**
  • Shortage – access to a skilled workforce to feed industry growth
  • Immediate needs: technical experts e.g. QPs and VV scientists
  • Long term: Operators
  • Skills Academy

• **Working with academia**
  • Lectures - EPSRC doctoral training centre, Regener8, KCL, UCL, Uni Sheffield, Uni Edinburgh, Termis and UKRMP Hub post docs
  • RCUK - Researcher in Residence (RiR)
Reflecting on the past 4 years
Learnings

01
Experienced executive team drawn from industry

Independent board of Directors

Advisory Panel drawn from industry and academia

02
Training through Immersion
2-3 year stint in the Catapult makes the individual highly valuable to industry especially in our high growth sector where skills deficits are very acute

03
Reputation that Catapult is a place to recruit industry ready experts

04
Recruitment, resource & succession planning - Attracting and retaining talent